Kecellitics Biotech Company Ltd
3 clinical trials · Sponsor
◉ Watch Kecellitics Biotech Company Ltd
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma (NCT05651100) | Kecellitics Biotech Company Ltd | 2022-12-10 |
| Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL (NCT04163575) | Kecellitics Biotech Company Ltd | 2020-02-01 |
Track Kecellitics Biotech Company Ltd automatically
Every clearance here is in the API, with alerts when new ones post.